Arcus Biosciences Inc

NYSE:RCUSUnited States

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Contact Information

Headquarters

3928 Point Eden WayHAYWARD, CA, United States 94545-3719

Phone

510-694-6200

Fax

302-730-1370

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder

Terry Rosen

President, Co-Founder

Juan Jaen

Chief Financial Officer

Robert Goeltz

Chief Operating Officer

Jennifer Jarrett

General Counsel

Carolyn Tang